FIG 3.

IgG recovered from patients during AIM and CONV neutralizes EBV infection of primary and cultured B cells. (A) IgG from AIM patient sera does not neutralize EBV infection of the Raji cell line; neutralizing activity was detected for serum IgG from the majority of individuals during CONV (58%) and the majority of CHRON individuals (72%). (B) In contrast, IgG recovered from most individuals during AIM (83%), all individuals during CONV, and all CHRON individuals neutralized EBV infection of primary cord blood B cells. (C and D) Correlation of individual patient blood viral load values during AIM with neutralization of EBV-infected Raji cells (C) or primary B cells (D). (E) Neutralization of EBV Akata infection by patient IgG is mediated by gp350-specific antibodies. Addition of 0.625 μg soluble gp350 to the neutralization reaction mixture reduced the effect of patient-specific neutralization of EBV infection in an IgG-dependent manner. P values were determined by the Mann-Whitney and Wilcoxon matched-pairs signed-rank tests *, P < 0.05; **, P < 0.01; †, P < 0.001; NS, not significant.